Azvudine Included in China’s COVID-19 Treatment Protocol
The National Healthcare Commission and the National Administration of Traditional Chinese Medicine have released a...
Policy / Regulatory
Shanghai Launches High-Quality Development Pilot for Public Hospitals
The Shanghai Municipal Health Commission (SHC) has released a notification regarding the public hospital high-quality...
NMPA Introduces Electronic Certificates for Biologics and Narcotic Drugs
The National Medical Products Administration (NMPA) has released a notification regarding the initiation of electronic...
CDE Releases Draft Guidelines for Tumor Therapeutic Vaccine Clinical Trials
The Center for Drug Evaluation (CDE) has released the “Tumor Therapeutic Vaccines Clinical Trial Technical...
CDE Releases 63rd Batch of Chemical Generic Reference Preparations
The Center for Drug Evaluation (CDE) has released the 63rd batch of chemical generic reference...
Jiangsu Launches Sunshine Procurement Platform for Drugs and Medical Consumables
Jiangsu province has launched its drugs and medical consumables sunshine procurement services website, providing a...
WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions
The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List...
India Launches Anti-Dumping Investigation Against Chinese Imports of Metronidazole
The Union Ministry of Commerce and Industry in India has initiated an anti-dumping investigation into...
China’s NMPA Proposes Reforms to Enhance Radiopharmaceutical Review and Approval
China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Opinions on Reforming...
China’s NMPA Releases 60th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 60th batch of reference drugs for...
China’s Volume-Based Procurement Cuts High-Value Medical Consumables Costs by 84%
The national high-value medical consumables alliance procurement office has released the results of the third...
BGI Genomics Added to US Defense Department’s Investment Ban List
BGI Genomics Co., Ltd, a leading Chinese gene sequencing firm, has reportedly been added to...
NHSA Releases Guide on Volume-Based Procurement Drug Equivalents
The National Healthcare Security Administration (NHSA) has reportedly released a reference guide for industry players,...
F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review
UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...
Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme
Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...
Beijing Designates 923 Medical Entities for National Reimbursement Drug List
The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of...
NHSA Launches Expert Review for 2025 NRDL Update in China
The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert...
Hainan’s Lecheng Zone Updates Special Drug Insurance List with Expanded Coverage
Hainan Boao Lecheng International Medical Tourism Pilot Zone has released an updated special drug insurance...
US Blocks Asymchem’s Acquisition of Snapdragon Chemistry
US authorities have intervened to block the purchase of US-based Contract Development and Manufacturing Organization...
CDE Issues Guidelines for Anti-Tumor ADC Clinical Development
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...